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An (un)desirable trade of harms? How elite athletes might react to medically supervised 
‘doping’ and their considerations of side-effects in this situation  
 
Background: The zero-tolerance approach to doping in sport has long been criticised. Legalising ‘doping’ 
under medical supervision has been proposed as a better way of protecting both athletes’ health and fair 
competition. This paper investigates how elite athletes might react if specific doping substances were 
permitted under medical supervision and explore athletes’ considerations about side-effects in this 
situation. The results are interpreted using a framework, which views elite sport as an exceptional and 
risky working environment. 
Methods: 775 elite athletes (mean age: 21.73, SD=5.52) representing forty sports completed a web-based 
questionnaire (response rate: 51%) presenting a scenario of legalised, medically supervised ‘doping’.  
Results: 58% of athletes reported an interest in one or more of the 13 proposed substances/methods. 
Athletes’ interest in a specific product was linked to its capacity to enhance performance levels in the 
athletes’ particular sport and depended on gender and age. 23% showed interest in either one or more of 
erythropoietin (EPO), anabolic-androgenic steroids (AAS), blood transfusions and/or Growth Hormone if 
permitted and provided under qualified medical supervision. Male speed and power sports athletes of 
increasing age had the highest likelihood of being interested in AAS (41%, age 36), female motor-skill 
sports athletes had the lowest (<1%, age 16).  59% feared side-effects. This fear kept 39% of all athletes 
from being interested in specific substances/methods whereas 18% declared their interest despite fearing 
the side-effects. 
Conclusion: Interpreting results with the understanding of sport as an exceptional and risky working 
environment suggests that legalising certain ‘doping’ substances under medical supervision would create 
other/new types of harms, and this ‘trade-off of harms and benefits’ would be undesirable considering the 
occupational health, working conditions and well-being of most athletes. Assessing the risks and harms 
produced/reduced by specific drugs when considering sport as a precarious occupation may prove useful 
in composing the Prohibited List and reducing drug-related harm in sport.  
 







This paper aims to contribute to discussions about the regulation of drugs in sport by empirically 
investigating how elite athletes might react if ‘doping’ was permitted under medical supervision and 
explore athletes’ considerations of side-effects in this situation. The implications of results, i.e., the trade-
off between harms and benefits1 of such approach for athletes, are interpreted using a conceptual 
framework that views sport as an exceptional and risky working environment.  
Today ‘doping’ is prohibited in sport mainly to secure a level playing field, to protect athletes’ health, 
to preserve the integrity of sport and to set a good example. Since the establishment of the World Anti-
doping Agency (WADA) in 1999 and particularly the implementation of the first World Anti-doping Code 
in 2004, anti-doping rules and efforts have undergone a process of intensification, standardisation and 
harmonisation. Today’s anti-doping programme is comprehensive (WADA, 2015) and, if caught, doping 
athletes risk four years’ ineligibility for a first-time doping violation. 
The current fight against doping faces multiple challenges, and the legitimacy of anti-doping efforts are 
greatly contested. For example, criticism has targeted a lack of clarity in the rationale justifying	the aims 
of anti-doping policy (e.g. Hanstad & Waddington, 2009; Mazanov & Connor, 2010; Møller & Dimeo, 
2014; Waddington & Smith, 2009), or the justifiability of doping bans (e.g. Savulescu et al., 2004; 
Tamburinni, 2007). It has been argued that the fight against doping is expressing a ‘moral panic’ executed 
as moral regulation (Critcher, 2014) or constituting a fear-based policy mirroring drugs myths from the 
non-sporting world, resulting in measures anchored in fear, morality and prejudice rather than in evidence-
based and reasoned arguments (Coomber, 2014) without any clear evidence-based knowledge of drugs 
side-effects (Kayser & Broers, 2015; Kayser & Smith, 2008).  
Others have argued that a zero-tolerance policy may have a negative impact on doping athletes’ health 
because it alters supply chains, pushing consumers from “culturally embedded dealers” towards the “black 
market” (Fincoeur, Van de Ven & Mulrooney, 2015). Furthermore, the current punitive approach has been 
denounced as ineffective in preventing athletes from doping (Kayser et al., 2007; Waddington & Smith, 
2009), a notion supported by empirical studies illustrating that athletes with doping experiences do not 
regard deterrence elements as credible (Engelberg et al., 2015; Kirby et al., 2011; Pappa & Kennedy, 




Further challenges facing anti-doping efforts are: firstly, the considerable differences in stakeholders’ 
interpretations and implementations of the Wada Code and International Standards worldwide (Dikic et 
al., 2011; Wagner & Hanstad 2011; Hanstad & Loland, 2005; Houlihan, 2014; Siekmann & Soek, 2010); 
secondly, flaws at all levels of the system, decreasing its effectiveness (WADA, 2013); thirdly, the very 
low detection rate (de Hon et al., 2015); and, fourthly, false negative (Ashenden et al., 2011; Lundby et al., 
2012) as well as false positive testing results (Delanghe, Bollen, & Beullens, 2008; Lundby et al., 2008).  
Furthermore, the paradoxes and unintended effects of anti-doping measures have attracted more 
attention in recent years. The paradoxes relate to how the comprehensive set of rules developed to protect 
athletes’ health and secure equality and fairness in sport have created new forms of inequalities between 
athletes subjected to different anti-doping regimes (Efverström et al., 2016; Hanstad, Skille & Loland, 
2010; Waddington, 2010; Overbye & Wagner, 2014; Overbye, 2016) and situations which may have 
negative effects on some athletes’ health (Bourdon, Schoch, Broers & Kayser, 2015; Overbye & Wagner, 
2013; Lentillon-Kaestner, 2013). Other issues of concern relate to: the collateral damage of excessive rule 
enforcement, e.g. the high proportion of athletes punished due to unintentional anti-doping rule violations 
(Cox, 2014; de Hon & Bottenburg, 2016; McArdle, 2015; Moston & Engelberg, 2016; Pluim, 2008), the 
unintended effects of the implementation of certain anti-doping rules, such as athletes’ negative 
experiences and emotions associated with their obligation to report their whereabouts (Bourdon et al., 
2015; Hanstad & Loland 2009, Overbye & Wagner, 2014; Valkenborg et al., 2014); challenges in the 
administration of Therapeutic Use Exemptions (Bourdon et al., 2015; Overbye & Wagner, 2013); unease 
during urine doping testing (Bourdon et al., 2015; Elbe & Overbye, 2014; Overbye, 2013, 2016); and, 
finally, athletes’ increasing worries about and avoidance of medicines for fear that they might be on the 
Prohibited List (NN).  
A critical appraisal of the zero-tolerance approach and the aims of this study   
In this context it is relevant to critically assess the benefits and costs of the system, for example with 
regard to not only its success in reducing doping (de Hon, 2016) but also its ability to reduce (and not 
cause) harm to athletes. Researchers have argued that the current anti-doping regime has gone too far in 




doping produces problems of greater impact than those which are solved (Møller & Dimeo, 2014; Kayser 
et al., 2007; Kayser & Broers, 2015). Hence, it has been argued that current anti-doping efforts have too 
many negative effects, are too extensive, yet too ineffective, and very costly (e.g. Kayser et al., 2007); 
from a public health perspective the cost of anti-doping is difficult to justify (Kayser et al., 2007; Kayser 
& Broers, 2012); and a relaxation of rules along with harm reduction measures may come at lower cost 
and/or with fewer consequences for society and the individual compared with the current zero-tolerance, 
abstinence-based approach (Kayser & Broers, 2012; 2015; Kayser & Tollener, 2017).  
Consequently, several researchers have argued that the current ‘zero tolerance’ approach to ‘doping’ is 
inappropriate and that implementing strategies based on harm minimisation would be better alternatives. A 
variety of alternative models for new drug-control policies in sport has been proposed aimed at protecting 
health as a replacement for the current punitive doping control measures (e.g. Kayser & Smith, 2008; 
Kayser & Broers, 2015; Kayser & Tollener, 2017; Kirkwood, 2009; Lippi et al., 2008; Steward & Smith, 
2015; Savulescu, 2015). Examples of such strategies are a relaxation of anti-doping rules within the 
boundaries of acceptable health risks, accompanied by harm-reduction measures (Kayser & Tollener, 
2017); and allowing ‘doping’ under medical supervision (e.g. Kayser, Mauron & Miah, 2005, 2007; 
Kirkwood, 2009; Savulescu, Foddy, Clayton, 2004; Smith & Steward, 2008). Some proposals also seem to 
be based on assumptions that ‘doping’ is widely used in elite sport and that (most) athletes will use 
‘doping’ regardless of either its impact on health or the illegal status of the drug. Furthermore, a key 
rationale behind suggesting legalisation or partial legalisation of drugs under medical supervision is the 
notion that the level of playing field is a myth and that the focus ought to be on minimising health harms 
rather than on punishment. In this way, it is expected that permitting drugs (or drugs to a certain limit) 
under medical supervision may provide athletes with a ‘healthier’ alternative because, firstly, athletes and 
doctors would not need to hide their involvement in using certain substances or methods and, secondly, 
the possible side-effects of different methods could be dealt with more effectively (e.g. Kayser et al., 
2005). Besides this, it has been argued that legalisation would increase fairness because all athletes would 
be given the same opportunity of using performance-enhancing drugs (Savulescu et al., 2004; Savluescu, 




Yet the proposals for legalising ‘doping’ or certain drugs such as anabolic-androgenic steroids (AAS) 
and erythropoietin (EPO) under medical supervision in sports are controversial and run counter to the 
intensification of anti-doping efforts recent years. However, although introducing different harm reduction 
approaches to drug use in society has become increasingly common (Cook, Bridge & Stimson, 2010), and 
shown to be useful in protecting the health of drug users in different settings, including among gym users 
(Kimergaard & McVeigh, 2014), we do not know if a radical change in the current strategy would actually 
reduce health risks in the social field of elite sport, or, how permitting ‘doping’ under medical supervision 
in sport would be received by athletes.  
To date, one drawback to any discussion on legalising ‘doping’ under medical care (and similar 
strategies) in an elite sport context is the lack of empirical studies informing discussions. In particular, 
researchers seldom consider ways in which the cultural and economic environment of sport may have an 
impact on legalised, medical supervised ‘doping’. Moreover, although it has been stressed that legalisation 
of doping might induce more athletes to use currently illegal drugs (Savulescu et al., 2004; Kayser & 
Smith, 2008); there is still a lack of discussion and reflection on what impact medically supervised 
‘doping’ (and similar strategies) might have on athletes in general and on whether athletes would be in 
favour of such change. Exceptions to this are the studies of Holm (2007) and Haugen (2011), both of 
whom apply a game theoretical approach, arguing, for instance, that legalising doping could create other 
problems and would not make doping a safer practice. Additionally Fry (2017) argues that the high levels 
of athletes support for anti-doping policy as well as the atypical harms from sports doping must be 
considered.  
Empirical studies suggest that athletes support certain limits as well as a control system but sometimes 
vary in their opinions on what it should be permitted to use (Christiansen & Møller, 2007; Lentillon-
Kaestner, 2015a; Overbye, 2013). When asked directly, few athletes favour legalisation of doping 
(Valkenburg et al., 2014; Fürhapter el al., 2015; Stamm et al., 2008) or report that they would start using a 
currently banned substance if it was removed from the list (Alaranta et al., 2006). Several studies have 
evaluated athletes’ reflections on ‘doping’ when its use is prohibited in sport, measuring their views on the 
influence of side-effects, the risk of being caught and/or medical supervision (Backhouse, Whitaker, & 




2013; Dimeo et al., 2013; Gucciardi, Jallah & Donovan, 2011; Overbye et al., 2013; Strelan & 
Boeckmann, 2006; Wulff, Mazanov & Connor, 2016). Importantly, in these studies ‘doping’ was 
considered an illegal practice and the name and particular characteristic of the particular substance was 
seldom disclosed to the athletes (possibly making it more difficult for them to assess). Since the issue of 
legality was still an issue, athletes’ reactions may (also) be understood as a measure of morality rather 
than a measure of their actual interest in using a certain drug if permitted, their willingness to run a severe 
health risk or their belief whether health risks would actually materialise. Hence, results from these studies 
cannot be understood as a measure of how athletes might react if ‘doping’ was legalised under medical 
supervision.   
Elite athletes’ opinions on and possible reactions to legalising ‘doping’ (or specific drugs like AAS 
and EPO) under medical supervision are important, especially considering that elite athletes are i) those 
who would be most affected, and ii) the main stakeholders when considering the legitimacy of anti-doping 
rules (Efverström et al., 2016; Overbye, 2016). Moreover, as pointed out by Møller (2010), one argument 
that both supporters and opponents of doping legalisation seem to agree on is that the interests of athletes 
should carry considerable weight. In spite of these considerations, no studies have so far investigated how 
a larger group of elite athletes might react to medically supervised ‘doping’, if permitted, or explored 
athletes’ thoughts about the side-effects of ‘doping’, if supervised by medical practitioners.  
Consequently, based on a questionnaire survey of 775 Danish elite athletes, the first part of this study 
investigates: i) how elite athletes may react to legalised, medically supervised ‘doping’ provided it took 
place under qualified medical guidance; ii) whether athletes would consider the side-effects in this 
situation; iii) if so, what side-effects they fear and what influence this fear has on their thoughts about 
trying the substances; and iv) whether athletes of different gender, age and type of sport differ in their 
responses. The second step is to consider what impact the introduction of medically supervised ‘doping’ 
may have on elite athletes in general – and whether this strategy would be a desirable trade-off between 
harm and benefit. The discussion of results is based on a conceptual framework which views elite sport as 
an exceptional and risky working environment. The final section concludes that anti-doping (as a drug-
regulation model in sport) may benefit to a higher degree from a risk-based assessment considering the 




It is, however, beyond the scope of this paper to outline the solution that could solve the current 
challenges. As noted by Kayser and Broers (2013), if an easy option existed, this would (most likely) 
already have been suggested and applied. Rather, the paper explores and introduces another view of drug 
regulation based on the notion of sport as an exceptional and often extreme working environment in which 
many actors interact and profit. Thus, the paper contributes to discussions of how ‘harms’ could be 
reduced in an elite sport setting. Furthermore, by presenting the challenges, possible reactions, 
deliberations and reservations from the athletes’ perspective, the study contributes empirical knowledge to 
an area which so far has been inadequately represented in current discussions about drug regulation in 
sport.  
Before presenting the methodological design and the results the theoretical inspiration and framework 
guiding the discussion and conclusions in this paper will be outlined briefly.  
Understanding elite sport as an exceptional and risky working environment  
This paper draws on Rhodes’ (2009) framework, which envisages a risk environment as comprising types 
of environment (physical, social, economic, policy) interacting with levels of environmental influence 
(micro, macro), to outline a conceptual framework that considers these elements in sport working 
environments.  
Elite sport constitutes a unique social practice comprising an exceptional and risky working 
environment.2 Drug use, as well as drug-related harm to health in sport, is shaped by and contingent upon 
the particular social context in which various actors interact and are mutually interdependent.   
Today, elite sport can be perceived as a social practice intertwined with the market, politics and 
medicine. The changing patterns of, and observable increase in, drug use in sport have been explained 
using concepts by Norbert Elias (1978) as two, largely autonomous sets of social processes in society (e.g. 
the medicalisation of life) and in sport (e.g. its professionalisation, politicisation, commercialisation), 
leading to an increased focus on results and competition (Waddington, 1996, 2000; Waddington & Smith, 
2009). Figurational sociology has been applied to understand issues related to the doctor-athlete 




how and/or why current anti-doping policy has numerous unintended consequences when implemented 
(Hanstad, 2009; Overbye, 2013, 2016; Waddington, 2010; Wagner, 2010).  
Although this paper does not have an explicit figurational framework, it is inspired by this approach, 
which provides a foundation for an understanding of the complexity of mutual interdependencies and the 
unpredictability of outcomes with regard to the regulation of drugs in sport examined in this paper.  
The elite sport figuration constitutes a matrix of mutually interdependent networks between individual 
and organisational actors (players), creating multiple layers of the game3 – a game which is played at 
regional, national, international and global levels. The synergistic relationships between key stakeholders 
have implications for other institutional and interpersonal relationships associated with sport (Anderson & 
Jackson, 2013). A figurational framework enables an understanding of the complexity of factors that may 
influence social practices in elite sport as well as the dynamic and changing character of these social 
practices. When the number of interdependent actors increases, social interaction becomes complex – and 
as a result uncontrollable – thus creating unpredictable games that are likely to lead to unintended 
consequences (Elias, 1978). These independencies may create both tensions and temporary equilibrium – 
providing opportunities as well as imposing constraints for human beings in their social dealings.  
This framework/understanding has at least two interrelated implications. Firstly, athletes’ use of 
various drugs must be considered in its social and cultural context, comprising interactions and 
interdependencies between individuals and environments. Secondly, a variety of different actors (including 
social, sporting and political institutions) potentially play an important role in harm production or 
reduction with regard to drug use in sport.   
In addition, Rhodes (2002, 2009) emphasises that one way of defining a risk environment is to see it 
as the space – whether social or physical – in which a variety of factors interact to increase the chances of 
harm occurring. Consequently, the following section provides an insight into some unique features in the 
particular working environment of elite sport (i.e. embedded in the sport figuration) which increase the 
risk of harm to athletes – and also help to explain why elite sport is replete with endogenous as well as 




Elite sport an occupation with endogenous and exogenous risks 
The dominant logic in elite sport is a competition logic governed by a win-lose code (Tangen, 2004) 
although other codes, for example enhancement/decline, clean/doped and healthy/unhealthy, may play a 
role as well (Wagner, 2009). Athletes are expected to be influenced by competition logic and always to 
strive for performance enhancement and victory (illustrated by the Olympic motto “citius, altius, fortius”). 
Embedded in the environment is a normalised ‘culture of risk’ (Bette, 2004; Safai, 2003; Nixon, 1992) in 
which pain and ‘playing hurt’ are normalised (Mayer & Thiel, 2016; Roderick, 2006a) – norms which may 
be internalised and encouraged by, for example, coaches, managers and doctors (Anderson & Jackson, 
2013; Safai, 2003; Roderick, 2006a; Waddington, 2015).  
The commercialisation and professionalisation of sport provide benefits for many different actors in 
the sport figuration. Simultaneously, commercial pressures place demands on various organisations and 
individuals to perform well continually (Anderson & Jackson, 2013). The organisation of work, 
employment models and working conditions may also have an impact on legal or illegal drug use and 
athletes’ perceptions of performance-enhancing drugs (Aubel & Ohl, 2014; Ohl et al., 2015; Smith, 2017). 
Athletes (as a labour force) are central to the success of sports organisations and teams, and sporting 
results are important for coaches’ and managers’ careers and financial opportunities (Andersen & Jackson, 
2013; Roderick, 2006a,b). Similarly, income and employment models, support from sports organisations 
or national funding bodies as well as sponsorship deals are often closely linked to the athlete’s or the 
team’s ability to continuously perform at a high level and deliver good results.  
Thus, athletes face significant occupational pressures to perform well or else risk replacement 
(Roderick, 2006b). Consequently, it seems likely that most elite athletes to some degree internalise the 
competition logic and the core norms of the sport ethic. At the same time, the many actors involved in the 
elite sports figuration, the interdependencies and intertwining logics with other fields (such as the market, 
medicine and politics) together create a unique and risky working environment which differs significantly 
from that of other social fields.  
The pivotal role of the body and the interdependence with sports medicine  




fragile and uncertain nature of athletes’ careers may add to the pressures on athletes (Roderick, 2006a,b). 
Several risks facing elite athletes can be directly associated with threats to the body’s functionality: the 
risks of injury, illness, declining performance and ageing (Bette, 2004; Roderick, 2006b). From this 
perspective, drug use may be seen as a coping strategy or predictable reaction to the inherent risks of sport 
(Bette, 2004; cf. previous section).  
In line with this, the significant role of doctors and the centrality of the doctor-athlete relationship 
with regard to drug use have been emphasised (Brissonneau, 2010; Hoberman, 2002; Waddington, 1996, 
2015; Waddington & Smith, 2009). Sports physicians have played a key role in pioneering the 
development and use of performance-enhancing drugs (Hoberman, 2002; Waddington, 1996). For 
example, extreme working conditions faced by cyclists in the 1970s led to closer cooperation with 
physicians and medical staff, whose reasons for providing drugs ranged from relieving the pain suffered 
by their ‘friends’ (the riders) to perceiving AAS as a logical treatment to ensure a ‘healthy’ working force 
(Brissonneau, 2010).  
The competing obligations and dilemmas facing doctors when providing drugs can also be seen, 
firstly, in the cultural and economic context (cf. previous sections), in which relationships between key 
stakeholders produce expectations and pressures on doctors that may compromise professional standards 
and/or the provision of healthcare (Anderson & Jackson, 2013); and, secondly, in the blurred lines and 
contradictory role of sports medicine, particularly the dual role of doctors in restoring athletes’ health 
while simultaneously preparing athletes for top performance (Tscholl, Feddermann, Junge, & Dvorak, 
2009; McNamee & Phillips, 2011). These challenges faced by doctors must also be considered from the 
perspective of the high demands placed on elite athletes’ bodies, which sometimes increase athletes’ needs 
for certain medicines. While injuries and some chronic illnesses (e.g. exercise-induced asthma) are an 
inevitable part of elite sport working life, the required treatments are often defined as doping. Cases of this 
sometimes blurred boundary between legal therapeutic treatment and the illegal use of medical substances 
occasionally occur when Therapeutic Use Exemptions (TUEs) are granted in elite sport (Overbye & 





Procedure and participants   
A total of 775 Danish athletes replied to a web-based questionnaire (response rate: 51%); of these 60% 
were male and 40% female athletes with an average age of 21.73 years. Forty sports were represented and 
grouped (drawing on Alaranta et al., 2006) according to the main physical demands of the sport. The 
overall distribution of athletes is set out in Table 1. Among the athletes supported by Team Danmark, 14% 
were categorised (by Team Danmark) as “world-class athletes” (i.e. ranked eight or better at the most 
recent world championship or Olympic Games); 26% were defined as “elite athletes” (national senior 
team athletes with a high level of performance); and 61% were “Team Danmark athletes” (mostly 
upcoming talented athletes in national teams for junior or senior). A majority of athletes regarded AAS, 
Growth hormone (GH), EPO and blood transfusions to have an effect in their sport. A contextualisation of 
athletes’ practices and preferences in relation to legal performance enhancing products, doping proximity, 
competition logic and norms in the training environment is set out in Table A1. 
>> Insert table 1<< 
Measures  
The findings presented in this paper were part of a survey assessing elite sport life and elite athletes’ views 
on and experience with legal performance-enhancing drugs and methods (Overbye, 2013). The questions 
were inspired by the scenario of medically supervised doping and by findings from 32 interviews with 
current and former elite athletes about their attitudes towards drugs and side-effects. 
Q1: Legal, medically supervised ‘doping’ scenario 
Athletes were invited to imagine the following situation:  
i) that the substances listed below were made legal;  
ii) that you could have the drugs provided; and 




Subsequently, a list of substances/methods was presented and the athletes were asked which substances 
they would be interested in trying. Some of the listed substances/methods were only illegal if a certain 
threshold level were exceeded or if certain brands were used.5 It was then noted that some 
substances/methods were currently prohibited whereas other were legal – and (again) it was emphasised 
that the athletes should answer as if all the listed substances and methods were legal. It was stressed that 
affirmative answers would not be interpreted as an indication that the athlete was currently using a 
particular substance, nor that the athlete was planning to do so in future. The degree of interest in trying a 
specific substance/method was reported by answering either: ‘yes’, ‘most likely yes’, ‘most likely not’, 
‘no’, ‘no, because I do not think it has an effect in my sport’ and ‘I really do not know’. In addition, an 
open-ended answer possibility was provided at the end of the question, enabling athletes to comment on 
the question or elaborate on their answers. The category “no, because I do not think it has an effect in my 
sport’ was introduced to discriminate between athletes who do not wish to use a specific drug and athletes 
who did not answer affirmatively because they did not think the drug would make a difference to their 
performance levels in their sport.  
Giving an affirmative answer to a question involving medically supervised ‘doping’ – even when one 
is told ‘doping’ is legal – must be regarded as particularly sensitive. Athletes’ use of doping is condemned 
(perhaps particularly in Denmark, where anti-doping measures also involve drug testing in some gyms as 
well as among recreational athletes); therefore, athletes might feel they are taking a great risk by reporting 
an interest in trying out say AAS or EPO. Consequently athletes were asked only if they were interested in 
trying a certain substance/method. Thus, the athletes report whether they would like to use a particular 
substance if this was legal; by answering affirmatively they do not commit themselves to systematically 
use the substance in higher doses over a longer period of time.  
Q2: Athletes’ reflections on side-effects  
A follow-up question asked whether athletes had considered any side-effects of the substances when they 
answered the first question (Q1). Athletes who reported they feared side-effects were subsequently asked 
how this fear influenced their answers in two follow-up questions. Firstly, if this worry made them refrain 




effects they worried about in an open-ended answer category. Secondly, if the athletes – despite their fear 
of side-effects – were interested in trying one or more of the listed substances/methods.   
Data analysis 
The data were analysed using SPSS 22. Bivariate distributions were used to examine the athletes’ degree 
of interest in different substances if these were legal and provided with qualified medical supervision as 
well as their considerations of side-effects in this situation and how (or whether) these depended on 
gender, age and type of sport. Differences were assessed using chi-square (x²) tests and gamma tests (two-
tailed). Values of less than 0.05 were considered statistically significant. Logistic regression was used to 
identify whether age, gender and sport type were significant predictors of interest in EPO and AAS. 
Dependent variables were recoded into binary variables (yes/most likely yes vs. no/ most likely no). Using 
logistic regression analyses (backwards manual stepwise elimination), two separate models were tested, 
one for EPO and one for AAS. Variables included in the logistic regression model were: i) gender, age 
[interval scale level] and type of sport [team sports/speed and power/endurance/motor-skill sports]. Both 
models included any two-factor interaction terms. “I don’t know/”No, because I do not think it has an 
effect in my sport” answers were excluded from the statistical analysis. Odds ratios (OR) and 95% 
confidence intervals are reported. 
Results 
How many elite athletes would be interested in trying different substances if legal and provided 
under qualified medical supervision? 
Results showed that many athletes would not be interested in trying different substances/methods 
even when legal and provided under qualified medical supervision (Figure 1). Vitamin and mineral 
injections were the most popular substance/methods (39%) and diuretics the least popular (10%). More 
than half (58%; n=450) the athletes would be interested in trying one or more of the 13 
substances/methods [25% indicated an interest in 1-2 substances; 23% in 3-6 substances and 10% were 




was not interested in trying the substance/method; ii) did not believe the substance/method would enhance 
performance levels in his/her particular sport [12% answered this in the case of 1-2 substances; 6% in the 
case of 3-6 substances and 4% in the case of 7-13 substances]; or iii) the athletes were unsure what to 
answer [17% were unsure what to answer in the case of 1-2 items; 7% in the case of 3-6 items and 5% in 
the case of 7-13 items].  
Almost one quarter (23%) of the athletes showed interest in trying at least one of the four assumable 
most effective performance-enhancing substances/ methods: EPO, AAS, blood transfusions and GH, if 
these were made legal and provided with qualified medical supervision. A minority (3%) would be 
interested in all four substances/methods: EPO, AAS, blood transfusions and GH; 4% in three out of the 
four; 8% in two of the four; and 9% would be interested in only one of the four substances/methods.  
>> Figure 1 << 
Would athletes of different gender, age and type of sport react differently to legalised, medical 
supervised ‘doping’? 
On a binary scale (yes/most likely yes vs. no/most likely not) using bivariate distributions, differences 
between groups of athletes were found in all items except one (diet medicines). Male athletes indicated 
interest more frequently than female athletes in trying: AAS (20% vs. 3%; p<0.001); blood transfusions 
(21% vs. 8% p<0.001); growth hormone (24% vs. 6%; p<0.001); EPO or similar means (23% vs. 6%; 
p<0.001); cortisone (22% vs. 4%; p<0.001); stimulating substances (27% vs. 9%; p<0.001); cognitive 
enhancing means (36% vs. 25%; p<0.03); and drops with sugar and salt as restitution between 
competitions (44% vs. 25%; p<0.001). On the other hand, female athletes more frequently answered they 
would be interested in trying medicines that could reduce nervousness (31% vs. 23%; p=0.024). Athletes 
20 years and older more frequently reported an interest in trying various substances/methods compared 
with athletes younger than 20 years of age: AAS (9% vs. 16%; p=0.005); blood transfusions (13% vs. 
19%; p=0.043); growth hormone (24% vs. 6%; p<0.00); EPO or similar means (13% vs. 20%; p<0.00); 
cortisone (10% vs. 20%; p<0.002); stimulating substances (14% vs. 24%; p<0.005); injection of vitamin 
or mineral supplements (32% vs. 47%; p<0.001) and drops with sugar and salt as restitution between 




Differences between sport types were found (in the following TS = team sports; SP = speed and 
power sports; MS= motor-skill sports; ES= endurance sports): endurance athletes more frequently 
reported an interest in blood transfusions (32% vs. TS: 13%/ SP: 12%/ MS: 9%; p<0.001); EPO or similar 
means (32% vs. TS: 15%/ SP: 15%/ MS: 4%); respiratory dilators (53% vs. TS: 30%/ SP: 30%/ MS:19%; 
p<0.001). Endurance and speed and power athletes more frequently reported an interest in trying 
stimulating substances (ES: 29%/ SP: 25% vs. TS: 16%/ MS: 12%; p=0.013) as well as drops with sugar 
and salt as restitution between competitions (ES: 49%/ SP: 44% vs. TS: 31%;/MS: 24%; p<0.001) 
compared with team sport and motor-skill athletes. Speed and power athletes more frequently reported an 
interest in trying AAS (SP: 19% vs. TS: 12%/ ES: 12%/ MS: 5%; p=0.046) and diuretics (SP: 18% vs. TS: 
8%/ ES: 13%/ MS: 9%; p=0.017). Moreover, speed and power and motor-skill athletes were more likely 
to be interested in cognitive enhancing means (SP: 40%/ MS: 42% vs. TS: 25%/ ES: 30%; p=0.004). On 
the other hand, athletes from motor-skill sports more frequently reported an interest in trying medicine to 
reduce nervousness (MS: 50% vs. TS: 22%/ SP: 28%/ ES: 18%; p<0.001).  
How do athletes vary in their interest in AAS and EPO if legal and provided under medical 
supervision?  
Anabolic-androgenic steroids  
Logistic regression analyses were conducted to predict the odds that athletes would be interested in 
trying AAS if legal and provided under medical supervision. The final model (cf. data analysis) was 
significant (χ2=61.37, df=5, p<0.000; Cox and Snell R2=0.096; Nagelkerke R2=0.177) and showed that 
type of sport, age and gender were significant predictors. The older the athlete, the higher the odds were 
that they were interested in AAS (OR 1.05 (95%CI=1.01-1.09); p=0.027). Male athletes had higher odds 
than female athletes for being interested in AAS (OR 9.68 (95%CI=4.13,22.71); p=0.00). Athletes from 
speed and power sports (OR 4.65 (95%CI=1.31,16.48); p=0.017), team sports (OR 3.03 
(95%CI=0.87,10.58); p=0.083) and endurance sport athletes (OR 2.66 (95%CI=0.70,10.01); p=0.151) had 
higher likelihood than motor-skill sport athletes of being interested in AAS, if permitted. Therefore, the 




was greatest among older male athletes from speed and power sports (e.g. 41%, 36 years old) and lowest 
among (younger) female athletes from motor-skill sports (e.g. <1%, 16 years old) (Figure 2).  
 
>> Figure 2 <<	
EPO or similar substances, e.g. CERA, NESP 
Logistic regression analyses were conducted to predict the odds that athletes would be interested in trying 
EPO or similar substances such as CERA, NESP if legal and provided under medical supervision. The 
final model was significant (χ2=54.73, df=5, p<0.00; Cox and Snell R2=0.092; Nagelkerke R2=0.16) and 
showed that type of sport, age and gender were significant predictors. The older the athletes, the higher the 
odds were that they were interested in EPO (OR 1.05 (95%CI=1.01,1.09); p=0.021). Male athletes had 
higher odds than female athletes of being interested in EPO (OR 3.58 (95%CI=2.03,6.33); p=0.00). 
Athletes from endurance sports (OR 14.48 (95%CI=3.26,64.43); p<0.000), team sports (OR 5.56 
(95%CI=1.27,24.29); p=0.023) and speed and power sports (OR 4.97 (95%CI=1.10,22.47); p=0.037) had 
a higher likelihood than athletes from motor-skill sports of being interested in EPO. Therefore, the 
probability that athletes would consider using EPO was greatest for male endurance athletes (e.g. 36 year 
old, 57%) – and increased with age – and lowest among younger female athletes from motor-skill sports 
(16 years old, 1%) (see Figure 3).  
>> Figure 3 << 
Do athletes consider side-effects when drugs are provided under medical supervision? If so, 
how does a fear of side-effects influence athletes’ reflections on using drugs?  
A majority of athletes (67%) stated they considered side-effects of the drug/method when reflecting upon 
which drugs/methods they would use. In the group of athletes who considered side-effects, 88% reported 
that they worried about side-effects while 12% did indeed consider the side-effects but were not afraid of 
these (see Figure 4). Of the athletes who were afraid of side-effects, 77% reported that this fear kept them 




of side-effects, they would like to try one or more of the listed substances if these were legal and provided 
under qualified medical assistance.   
>> Figure 4 << 
A total of 154 athletes commented on the side-effects they feared when answering the first question (Q1). 
In addition, eight of the 17 athletes who elaborated on their answers in the open-ended answer option in 
Q1 also raised concerns about side-effects. Athletes named i) particular side-effects they feared, ii) 
specific substances/methods they feared; iii) their reservations when answering the question; or iv) had 
other explanations or comments (See Table A2 in the Appendix for an overview). Below are some 
indicative responses:  
 
Fear of hormones: “If we assume that all are legal, I would not dare to use hormones and drugs 
which change the body or can have a damaging impact on body organs, etc.” (female athlete, 
endurance sport)   
	
Drugs if needed: “I would only use some of the listed substances if I had trouble with, for 
example, injuries or with my diet” (female athlete, team sport)  
 
Unwilling to run health risks: “I would demand documentation saying that there are – or there 
would be – no side-effects. My sport is not more important than my health” (male athlete, motor-
skill sport) 
 
Competition logic and accepting risks: “Yes and no, because if everything was legal, then 
everyone would also take the listed substances. And then, although it was dangerous, it would 
just be something everyone did to play sport at a high level of performance” (male athlete, team 
sport) 
 
Fear of permanent damage: “Several of the substances/methods can result in permanent 
damage, including brain damage, like Ritaline (which could be relevant in my sport), so I would 
check out the long-term side-effects beforehand” (female athlete, motor-skill sport). 
 
Lack of trust in doctors: “Lack of knowledge and disagreement among medical doctors, so I do 
not dare trust them” (male athlete; team sport)  
	
Great trust in doctors: “I thought that some of the substances might have deadly side-effects; 
however, the correct supervision made me surer that I would use some of the substances” (male 






The first set of questions set out to explore how elite athletes may react if ‘doping’ was legal and provided 
under qualified medical supervision. A key finding was that approximately three quarters of the athletes 
were not interested in trying AAS, EPO, GH and/or blood transfusions, even if permitted in sport and 
provided under qualified medical guidance. Additionally, although the results reveal great variations 
within the athlete group, more than half of the athletes (cf. Figure 1) would not be interested in trying 
some of the less effective performance-enhancing substances, including products with little or no (or even 
a possibly positive) impact on health. The great variations within the athlete group are to be expected 
when one considers the differences in their approach to legal performance-enhancing drugs: these are, 
firstly, the differences in the patterns of their sport-related use of legal products, for example caffeine, 
creatine and NSAIDs (Table A1; Overbye, 2013:123); secondly, differences in their practices related to 
(de)selecting legal products, e.g. whether they had ever refrained from or minimised their use or felt it was 
important to enhance performance with all available legal products (cf. Table A1); and, thirdly, the 
differences in how the athletes said they would react if (when) competitors started using a new legal 
performance-enhancing drug e.g. if they would use the same drug or they would (prefer to) continue to do 
what they normally did (Table A1). Moreover, as an example, athletes’ use of or refraining from use of 
caffeine pills (Table A1) exemplifies how the athlete group (particularly endurance athletes) have engaged 
with a previously prohibited substance (prohibited before 2004 in doses above 12µg/ml). This 
corroborates the results that a majority of the athletes would not be interested in using less performance-
enhancing products even if legalised (Figure 1).  
Explanations for some athletes’ lack of interest in strongly performance-enhancing drugs or diet 
medicines were found in the studies, showing that some athletes feel that good results and changes in body 
composition (e.g. reduction of weight, body trimming) should be earned through hard work, i.e. through 
strict training regimes and appropriate diet (Overbye, 2013; Overbye et al., 2013; Rasmussen, 2012), and 
would prefer to know that they – and not a drug – are responsible for good performance (Overbye, 2013). 
In this respect, some athletes perceive specific drugs or specific effects of drugs as less acceptable ‘short-
cuts’. The route of ingestion may also influence athletes’ interest: for example, some may dislike or fear 




(Tangen, 2004) was not explicitly or sufficiently presented in the methodological design of this study: i.e. 
if their competitors decide to start using very effective performance-enhancing drugs, athletes might need 
to react if they wish to retain their position. And sporting networks, clubs or organisations may encourage 
or even demand their use in this situation. Thus, when athletes reported their reflections on which 
substances they would be interested in trying, they may not have considered the possible dilemma that 
would occur if ‘doping’ was in fact legalised. Furthermore, the questions were not linked to a specific 
situation/social context other than that the specific (named) drug was permitted and qualified medical 
supervision was assured. Considering the multiple circumstances acting as incentives and protective 
factors for ‘doping’ when it is prohibited (Erickson, McKenna, Backhouse, 2014; Overbye et al., 2013), 
particularly situations in which the athletes’ sporting career and future employment are at risk (e.g. 
injuries) may induce a greater proportion of athletes to use specific drugs if legalised and medically 
supervised.  
Other explanations may involve a fear of the side-effects of the drugs taken (cf. Figure 2; Table A2) 
or strongly internalised anti-doping norms and values that regard taking AAS and EPO, for example, as 
cheating, dangerous and something that fundamentally contradicts what sport is about (see WADA, 2015). 
In line with this, it could be argued that athletes’ (internalised) cultural scripts (Rhodes & Bivol, 2012) 
reflecting social values on drug use may influence their responses. Here, athletes may not personally feel 
that they have made judgements on drugs when answering the question. In addition, even if removing the 
illegal aspect of ‘doping’ would decrease the sensitivity of the question some responses could be 
interpreted as socially desirable answers (Petróczi & Haugen, 2012).  
The questions aim to measure micro level responses and considerations from athletes in the situation 
of legal, medical supervised, ‘doping’. Agreement between athletes’ answers (Figure 1) and their practices 
and preferred reactions with regard to less performance-enhancing legal products (cf. previous section; 
Table A1) suggests that athletes could relate to the question/situation with regard to less performance-
enhancing products. But particularly those athletes who did not encounter ‘doping’ in their close 
proximity and/or who refrained from using a variety of legal products (Table A1; Overbye, 2013:123) 




The study design cannot predict whether athletes will indeed react in the way they say if a specific 
substance was in fact legalised. However, the understanding of elite sport as an exceptional and risky 
environment (cf. the conceptual framework) suggests that the athletes’ ‘real life’ responses to different 
drug use will be influenced by not only the specific social and cultural context but also the complex 
interactions and interdependencies at different levels of the sport figuration. In this context, athletes may 
change preferred reactions to different drugs or be forced to do so to cope with the (new) working 
conditions.  
The impact of gender, age and type of sport 
A further main finding relates to the great differences within the athlete group, showing that interest in 
trying specific substances often varies significantly according to athletes’ gender, age and type of sport. A 
relatively large proportion of male athletes in this study who were older, and particularly those from sports 
which would benefit from a particular substance, were interested in trying EPO or AAS if legal and 
provided with qualified medical supervision. Female athletes (of all ages) and in particular those from 
motor-skill sports, on the other hand, were less likely to show interest in very effective performance-
enhancing drugs/methods – although interest among female athletes likewise varied according to sports 
type and increased with the age of the athlete. The gender difference was expected as several studies have 
suggested that male athletes are more likely than female athletes: i) to be open towards or use doping 
(Alaranta et al., 2006; Lucidi et al., 2008; Pitsch & Emrich, 2012); ii) to be curious about how ‘doping’ 
can enhance their performance and to have personally explored whether legal substances might enhance 
their performance (Overbye, 2013); and iii) to disagree that they do not want to achieve a great 
performance-enhancing effect induced by a drug (Overbye et al., 2013).   
The finding that interest in trying a specific substance often increased with the age of athletes of both 
genders collaborates the findings of other studies (Brissonneau, 2010), and that ‘older’ athletes were more 
likely to regularly consume a variety of legal performance-enhancing products (Overbye, 2013) and to 
(hypothetically) consider using illicit drugs if these could help reduce the damage to the body caused by 




In keeping with the notions put forward by Alaranta et al. (2006) an important finding of relates to 
differences between types of sports, which showed predictable patterns of interest, particularly among 
male athletes. In particular, athletes from the type of sport that would benefit most from a specific 
substance were also more likely to be interested in that substance. The results confirm the notion that the 
use of legal and illegal substances in sport may often be understood as a means to an end and not an end 
goal (Petroczi & Aidman, 2008). Thus, the results suggest that legalisation of ‘doping’ or of specific 
products are likely to have a varying impact in each sport discipline. Moreover, legalising ‘doping’ (or 
drugs with a great performance-enhancing and potentially health-damaging impact) would create a larger 
gap between athletes who might want or dare to use AAS, GH or EPO, for example, and those who do not 
wish to or are afraid to do so.  
A functional use of drugs also implies that some of the athletes who currently use ‘doping’ may not 
particularly enjoy this practice but may have engaged in ‘doping’ to respond to a particular working 
environment, which, in turn, suggests that the context (i.e. the working conditions and local environment) 
needs to be altered if ‘doping’/drug prevention and the minimising of harms is to be sustainable (Aubel & 
Ohl, 2014; Bette, 2004; Overbye, 2013). Consequently, while legalising or partly legalising ‘doping’ 
together with harm reduction measures may offer a better chance of protecting doping athletes’ health, it 
seems little likely that all athletes (doping and non-doping) would appreciate a legalisation of ‘doping’ 
(Valkenburg et al., 2014; Fürhapter el al., 2015; Stamm et al., 2008). Furthermore, the guarantee of a ‘safe 
environment’ is challenged by the ‘competition logic’ (Tangen, 2004) as well as the particular demands 
and the characteristics of the elite sport figuration. 	
Considerations of side-effects if ‘doping’ was legalised under medical supervision 
The second set of questions addressed the question of whether athletes considered side-effects. An 
important finding was that the assurance of having a drug provided under qualified medical supervision 
did not remove a majority of the athletes’ fear of side-effects.  
The finding that one third of the athletes did not think of side-effects when reflecting on drug use 
corroborates results of other studies (Kirby et al., 2011; Lentillon-Kaestner & Carstairs, 2010; Lentillon-




about health risks are embedded in most anti-doping literature/ education programmes/ campaigns (e.g. 
WADA, 2016) and that substances may be included on the Prohibited List because of their actual or 
potential health-damaging effects (WADA, 2015). One explanation might be that athletes had not yet 
faced the situation in which they felt they needed to consider whether or not there were side-effects 
because they i) seldom or never answered affirmatively; or ii) they just did not consider using those 
substances commonly linked to health risks (AAS, EPO and GH). If ‘doping’ were legalised, however, 
these athletes might need to make a decision for or against using certain drugs, particularly if they 
compete in a sport in which ‘doping’ makes a great difference to performance and they wish to maintain 
their position. If so, the number of athletes who may worry about side-effects is likely to increase.  
On the other hand, if the health side-effects of, for example, AAS, EPO and GH are overestimated – 
or at least not properly based on evidence (Coomber, 2014; Kayser & Broers, 2015) – legalisation, 
combined with conveying this information to athletes and providing medical guidance, may lower the 
number of athletes who worry about side-effects. Previous studies, however, suggest that athletes consider 
health side-effects as a reason for refraining from ‘doping’ (e.g. Backhouse et al., 2013; Bloodworth & 
McNamee, 2010; Gucciardi et al., 2011; Strelan & Boeckmann, 2006; Overbye et al., 2013), and although 
many athletes believe that the health side-effects of ‘doping’ are exaggerated on purpose to scare athletes 
(Overbye, 2013), the fear of health side-effects related to certain drugs seems to be internalised among a 
high proportion of the athletes surveyed. A female endurance athlete confirms this when elaborating on 
her fear of hormones and any drugs that may change or damage the body (see the quotation concerning 
‘fear of hormones’). Similarly, a male motor-skill sport athlete stated that his health was more important 
than his sport and that he was unwilling to run health risks induced by a drug (cf. quotation ‘unwilling to 
run health risks’). A recent study has found that past use of AAS increases the risk of Systolic 
Hypertension in men years after they have stopped using them (Rasmussen et al., 2016). Particularly (and 
unsurprisingly) the prospect of long-term permanent damage to the body seems to frighten many athletes 
(see Table A2; quotation ‘fear of permanent damage’).  
One important finding was that a majority of athletes who feared side-effects reported that their fear 
kept them from wanting to try one or more of the substances/methods listed, although one in five would be 




legalisation of ‘doping’ would induce a greater number of athletes to use those drugs whose side-effects 
they fear. These findings illustrate why arguing for legalisation based on the view that athletes are free to 
choose not to dope (Tamburrini, 2007) and that legalisation would put athletes on a par with doping 
athletes (Savulescu et al., 2004) seems less convincing when elite sport is perceived as an exceptional and 
risky working environment and the focus is on seeking to protect occupational health and well-being. 
Furthermore, the results suggest that refraining from using drugs may relate to a concrete fear of side-
effects, and not necessarily to personal moral beliefs which condemn drugs.  
In general, the results corroborate the findings of other studies suggesting that many athletes are 
unwilling to run severe health risks in order to guarantee sporting success (e.g. Bloodworth & McNamee, 
2010; Bloodworth et al., 2010; Connor et al., 2013; Overbye et al., 2013; Wulff et al., 2016). Yet studies 
also reveal that quite a large number of athletes show interest in a very effective performance-enhancing 
drug if its use is not associated with serious health risks (Connor et al., 2013) or if a drug is provided with 
qualified medical supervision and its use may reduce damage to the body caused by strenuous training, 
competitions or injuries (Overbye et al., 2013). Access to qualified medical supervision seems to be of 
great importance (Overbye et al., 2013), and it is commonly expected that qualified medical supervision 
will reduce the side-effects of drugs (Kayser et al., 2005; Savulescu, 2015; Steward & Smith, 2015). The 
prospect that doctors (and support personnel) will act in the best interest of the athletes’ health and will be 
able to decide cases in which drugs can or cannot be used seems to be a presumption in some of the 
suggestions in new drug-control policies (Savulescu, 2015; Steward & Smith, 2015). Key questions are 
whether qualified medical supervision can be assured; whether doctors act in what they believe to be the 
best interest of athletes; whether there is consensus among doctors about best practices; and, for example, 
what doses would be appropriate. These questions were brought up by a male team sport athlete who 
pointed out that the lack of knowledge of and disagreement among doctors made him distrust doctors (cf. 
quotation ‘lack of trust in doctors’). By contrast, a high degree of trust in medical supervision was 
reported by another male team sport athlete (cf. quotation ‘trust in doctors’) who felt that correct 
supervision would make him more confident to use some of the substances, even though he thought that 




Agreeing to drug use only under specific conditions – e.g. as a reaction to circumstances posing a 
threat to a sporting career (Bette, 2004; Hauw & Bilard 2012; Overbye et al., 2013) was exemplified by a 
female team sport athlete who stated that she would only use some of the listed substances if she was 
troubled with injuries or her diet (cf. quotation ‘drugs if needed’). On the other hand, a male team sport 
athlete seems to have internalised the competition logic as well as the common norms of elite sport, and 
expected other athletes to think like him, i.e. the legalisation of ‘doping’ would lead everyone to ‘dope’ in 
order to play sport at a high performance level although it was dangerous (cf. quotation ‘competition logic 
and accepting risks’).  
The results of the current study, however, suggest that athletes act in different ways and that it is 
unlikely that all athletes will adhere to the ‘competition logic’ (Tangen, 2004) when it comes to potentially 
very effective performance-enhancing drugs such as EPO, AAS and GH.6 Similarly, athletes report 
differently about how they would react to competitors’ use of legal performance-enhancing medicines and 
how (if) coaches or sporting organisations views have an impact on their use (Overbye, 2013:141; Table 
A1), whether they would evaluate their competitors’ doping (when prohibited) as an incentive (Overbye et 
al., 2013) and if they would be willing to compete hurt in the work context of elite sport (Mayer & Thiel, 
2016). Furthermore, if severe health risks are anticipated, this would prevent many athletes (cf. Figure 2) 
from reacting by using the same drug, thus adding a dimension of unpredictability to the ‘game’ of 
legalised, medically supervised ‘doping’.   
From the preceding it can be seen that the legalisation of ‘doping’ in the risky working environment 
of sport is likely to influence working conditions and occupational health. The following section will 
interpret the implications of results in a broader perspective, discussing whether (and when) legalising 
specific ‘doping’ substances under medical supervision might create a desirable trade-off of harms when 
focus is placed on protecting athletes’ working environment and their occupational health – and 
understanding sport as an exceptional and risky working environment (cf. the conceptual framework). 
An (un)desirable trade of harms?  
One important notion with regard to the ‘trade of harms and benefits’ is the perspective that anti-doping 




doping substances) (Kayser & Broers, 2012; 2015) and that the focus ought to be placed on minimising 
health risks for drug users rather than punishment. This paper argues that the impact of ‘doping’ on the 
working environment and on the occupational health of all athletes must also be considered a key factor.  
Thus, to evaluate the implications of the results some key, and interrelated, questions must be 
considered – questions relating to the extent to which athletes’ working conditions, external pressures and 
occupational risks may change if a specific drug/method is legalised. The impact/change may depend on: 
the causation, reduction or change of ‘individual’ and ‘social’ harms (which may relate to the possible 
impact on the prevalence of a specific drug); whether the drug significantly enhances performance levels 
in the athletes’ particular sport; its impact on health; and whether qualified medical supervision can be 
guaranteed. At the same time, the analysis must seek to distinguish between harms arising from drug use 
and those caused by the drug control system itself.  
Prevalence  
The analysis suggests that that legalisation of substances such as AAS and EPO is likely to significantly 
increase their use (cf. previous sections). Each year, while fewer than 2% of doping tests show positive 
test results (WADA, 2016), studies estimate a significantly higher prevalence of ‘doping’ among specific 
athlete groups (de Hon et al., 2010; Pitsch & Emrich, 2012; Striegel, Ulrich & Simon, 2010). Despite great 
unpredictability inherent in the ‘game’ of legalised medically supervised ‘doping’ (cf. previous sections; 
the conceptual framework) and in predicting ‘real life’ responses to drug uses, it seems plausible to 
assume that removal of the illegality aspect of ‘doping’, accompanied by qualified medical supervision, is 
likely to be decisive for athletes’ interest (for example, for the 20% of male and 3% of female athletes who 
reported most likely to be interested in trying AAS if permitted and provided under qualified medical 
supervision). 
Performance-enhancing effect 
Whether a drug/method significantly enhances performance levels in an athlete’s particular sport may 
contribute knowledge about whether or not legalisation (or the legalisation of specific drugs) may create 




endogenous and exogenous risks). WADA’s Prohibited List contains more than 300 substances/methods 
(WADA, 2017), and their performance-enhancing impact varies between sports (de Hon, 2016). Thus, 
drawing clear conclusions on the harm causation/reduction of ‘doping’ is a difficult task and beyond the 
scope of this article. However, the current study covers different scenarios by introducing both 
substances/methods with the greatest potential to enhance performance levels (in most sports) and a 
selection of products/effects with some or little performance-enhancing impact (some of which may 
potentially improve athletes’ health in certain situations). Hence, the study illustrates the large difference 
in impact of legalisation depending on the particular drug/method (and type of sport), as exemplified 
below in the cases of EPO and respiratory dilators.  
The survey results indicate that athletes in general would prefer not to use EPO. Therefore, allowing 
EPO up to a specified haematocrit limit while monitoring its use and impact on health (Kayser & Tollener, 
2017; Savulescu, 2015) is likely to create new forms of inequalities between athletes and to put additional 
pressure on the majority of athletes, who currently either would prefer not to enhance performance with 
EPO or are afraid to do so. The situations in which a great majority of athletes already use EPO constitute 
a different case. Although it is uncertain whether legalisation and provision under medical supervision will 
reduce overall harms, implementing harm minimisation strategies are likely to reduce harms in the case of 
individual athletes using EPO (Kayser & Tollener, 2017; Savulescu, 2015), and to be an more efficient 
doping approach when it matches the athletes behaviour towards doping and injection use (Lentillon-
Kaestner, 2015b). However, considering the results of this study, the great majority of athletes – in 
particular younger athletes and female athletes – are likely to suffer if EPO has a significant performance-
enhancing impact in their sport and is permitted and provided under medical supervision.  
Legalising respiratory dilators, e.g. common asthma medicines, may have a different impact on 
athletes’ working environment. Relatively few of the surveyed athletes without diagnosed asthma or 
experience of asthma symptoms (19%) would be interested in trying respiratory medicines if permitted. 
Considering, firstly, this result and its implications; secondly, that common medications like inhaled 
glucocorticoids (Kuipers et al., 2008) and beta2-agonists (Pluim et al., 2011) cannot be proven to enhance 
physical performance in regular doses; and, thirdly, the obstacles for current TUE administration 




look at some of these products and change the way they are regulated within the anti-doping framework 
would seem a plausible solution that is likely to relieve more harms that it produces. 
At a micro level, the results suggest that the legalisation of very performance-enhancing ‘doping’ 
substances may have an impact on power dynamics in training environments where good 
results/performance determine who has most influence, who will get most attention from the coach, and 
where social norms involve showing a willingness to make sacrifices for the sport (Table A1; cf. Elite 
sport an occupation with endogenous and exogenous risks). An increase in work-related stress and 
dilemmas is likely to occur in the case of athletes who are unwilling to use, or worry about using, AAS, 
GH and EPO (Figures 1 and 2; Table A2), or are unwilling to use these systematically, and who 
simultaneously believe in these drugs’ great capacity to enhance performance levels in their sport (cf. 
Table 1). This would compound the stress already experienced by a considerable number of athletes 
operating in a working environment in which worries about the possible social, sporting and financial 
consequences of not performing as expected are frequently experienced (Overbye, 2013:110).  
Health   
Knowing about the side-effects of substances and methods may contribute knowledge not only about 
whether athletes may be forced into running additional health risks but also about whether legalising some 
drugs under medical supervision may sometimes reduce health risks in elite sport. The health impact of 
drugs on the Prohibited List will vary; and the examples provided in this article illustrate the complexity. 
Many substances on the Prohibited List are medicines which may help individuals to regain health when 
having a medical need. However, it seems plausible to assume that the effects of drug consumption on 
health will greatly depend on dosage, frequency of use, route of entry and whether it is single or poly drug 
use (Coomber, 1999). Thus, the impact may depend on whether the drugs can be monitored and kept 
within ‘safe’ doses in the context of sport. Furthermore, the results of this study show that if severe health 
risks are anticipated, many athletes would tend not to use the drug (Figure 2). Thus, when considering the 
well-being of athletes, it is essential to take into account the majority of athletes feared side-effects as well 
as those athletes who – despite fearing side-effects – would be willing to use a drug if it was legalised and 




Qualified medical supervision  
Whether qualified medical supervision can be ensured in a sporting context is essential for reducing drug 
harm. An important challenge in this respect is posed by the working conditions and by the expectations 
various groups and individuals have of doctors who work with athletes (Anderson & Jackson, 2013; Holm 
et al., 2011; Waddington, 2015). Pressures and demands may vary depending on whether the doctor is 
employed by a private club or a sports organisation or is a general practitioner (Holm, McNamee, & 
Pigozzi, 2011; McNamee & Phillips, 2011) and may sometimes lead them to compromise professional 
standards (Andersen & Jackson, 2013) with less focus on protecting athletes’ health (e.g. Roderick, 2006a; 
Waddington & Roderick, 2002). Furthermore, the variations in doctors’ diagnosis and prescription 
practices (Tshcoll & Dvorak, 2012) suggest that ‘best practices’ with regard to medical supervision may 
vary greatly between doctors and possibly between continents.  
Beyond the aspect of the ‘culture of risk’ and athletes’ interdependence with other actors in the elite 
sports figuration who likewise may be judged by (and profit from) athletes’ results/performances, it seems 
unlikely that drug use in elite sport will always be based on well-informed choices by athletes nor that 
professional medical advice when supervising drug use will always be grounded in a genuine interest in 
protecting athletes’ health. From this perspective, the legalisation of strongly performance-enhancing and 
health-damaging drugs would add additional risks to an already risky occupation.  
Another aspect to be considered if strongly performance-enhancing and health-damaging drugs are 
permitted relates to differences in the accessibility of drugs, as well as athletes’ financial circumstances 
and how differences in resources may have a great impact on athletes’ (and their support networks’) 
opportunities to actually choose the “healthiest” option and have access to qualified medical supervision.  
In addition, the analysis must consider that harm to athletes’ health and wellbeing also arise from the drug 
control system (anti-doping) (cf. Introduction). Each policy element (i.e. doping controls, whereabouts 
reporting and the TUE system, as well as the Prohibited List and the sanctioning paradigm) has its own 
purpose, faces different challenges and, to a varying degree, has unintentionally had a negative influence 
on the working conditions and wellbeing of a number of athletes. Examples of this influence among some 
of the athletes’ surveyed include negative emotions linked to: i) specific policy elements and how these, 




stress and discomfort; cause frustration; arouse feelings of unfairness; are too time consuming; and lead to 
athletes being confronted with administrative obstacles (Elbe & Overbye, 2014; Overbye, 2013, 2016; 
Overbye & Wagner, 2013, 2014); and ii) athletes’ worries or fears of mistakenly committing an anti-
doping rule violation, which influence some athletes’ daily lives and practices and, potentially, health, e.g. 
when avoiding medicines despite a need (Overbye, 2013).  
Taking into account that, despite their negative experience of and low level of trust in the 
effectiveness and fair implementation of anti-doping policies world wide, a great majority of athletes 
support or accept anti-doping as a principle, including key measures (e.g. Bourdon et al., 2015; Overbye, 
2013, 2016; Overbye & Wagner, 2013, 2014), and considering the results of the present study interpreted 
with the understanding of sport as an exceptional and risky working environment (in which legalising 
certain ‘doping’ substances under medical supervision might create other/new types of harms without 
having the capacity to ensure the protection of drug-using athletes’ health), the potential for minimising 
the harms of anti-doping measures must be considered. 
Limitations  
This study only surveyed Danish athletes’. It is likely that national context may have an effect on the way 
in which athletes respond to legalised, medically supervised doping and how side-effects are evaluated. 
The study does not measure how far the athletes would be willing to go in terms of the doses taken and the 
frequency. Furthermore, athletes responded to the question with the expectation that the medical 
supervision would be ‘qualified’. Yet ‘qualified’ medical supervision may – as discussed in this paper – be 
difficult to ensure in a sporting context, and even doctors may disagree about what this entails.  
The article measures neither athletes’ attitudes to ‘doping’ or legalisation per se nor their interest in 
using specific drugs when prohibited in sport. Athletes’ interest in specific products cannot be interpreted 
as the athlete indicating that they would use the drug if prohibited or that they would wish the drug to be 
legalised. However, by removing the illegal aspect of ‘doping’, the risk of socially desirable answers 
decreases. Thus, the results may provide insights not only into athletes’ interest in trying specific 




The article does not consider (or evaluate) the overall impact of medically supervised ‘doping’ on 
society or public health; nor does it inquire into the costs from a societal perspective, which were focal 
points in some of the studies arguing for a radical change in the current drug control model (Kayser et al., 
2007; Kayser & Broers, 2012; 2015; Kayser & Tollener, 2017).  
Concluding remarks and implications  
Considering the results of this study while viewing elite sport as an exceptional and risky working place 
suggests that a legalising of strongly performance-enhancing and potentially health-damaging substances 
under medical supervision might open a Pandora’s box of uncertain outcomes, likely to lead to 
unpredictable games with unintended consequences for a greater number of athletes but without the 
capacity to truly ensure the protection of drug-using athletes’ health. From this perspective, the rules 
prohibiting ‘doping’ can be regarded as rules seeking to protect workers’ health. Hence, some kind of drug 
control is needed to seek to protect athletes (workers) from exploitation by their surrounding environment 
as well as to reduce the magnitude of occupational health risks in an already risky working environment. 
Although the current drug regulation model faces a great variety of challenges, the solution of permitting 
strongly performance-enhancing and health-damaging doping substances under medical supervision 
would create new types of harms for athletes and that this trade-off between harms would be unwanted 
from the perspective of most athletes. Therefore, if the aim is to protect health and secure fairer 
competition for athletes in general, the legalising of certain ‘doping’ substances under medical supervision 
seems to be an inappropriate strategy. 
However, not all prohibited substances are performance enhancing and issues of health in relation to 
some drugs and their impact on working conditions are ambiguous, and this complexity calls for a 
reconsideration of anti-doping policies, in particular the Prohibited List. All stakeholders involved in anti-
doping should question whether the limits set today, along with the rationales behind including substances 
and methods in WADA’s Prohibited List remain appropriate and whether the inclusion of specific 
substances/methods might increase harms. A stronger emphasis on reducing the negative effects and 
harms of the current drug model, for example, actively seeking to minimise the negative effects of anti-




To reduce drug-related harms in sport and minimise harms associated with the Prohibited List (e.g. 
the high number of unintentional doping cases), those composing the Prohibited List could draw to a 
greater degree on an assessment and differentiation of the individual and social harms produced or 
reduced in the particular working environment of elite sport and within different sport disciplines. Such 
assessment might be carried out as a multi-criteria decision analysis undertaken by expert groups from 
relevant fields (Manning, Wong, Ransley & Smith, 2016; Nutt et al., 2010; van Amsterdam & van den 
Brink, 2010), albeit assessing the specific characteristics of individual and social harms in a sporting 
context with a focus on occupational health and working conditions, and aiming towards a strategy/model 
most likely to result in a net reduction of harms in the working environment of elite sport. 
From this point of departure, and considering the framework (i.e., protection of occupational health 
and wellbeing and working conditions in a risky working environment) and results of the current study, a 
simplified matrix may consider prohibiting drugs/methods likely to increase social and individual harms 
(e.g. strongly performance-enhancing/performance enhancing and potentially health-damaging drugs) in a 
specific sport. By contrast, drugs which only, or mainly, produce individual harms (e.g. not/scarcely 
performance-enhancing drugs) may be better dealt with via harm minimisation programmes and 
prevention measures (such as promoting structural or cultural changes that may reduce demands for 
certain drugs in sport). Although, in some sports a B-List and a disciplinary system may be required, i.e., 
if an athlete’s use of a none/scarcely performance enhancing drug possess a health/safety risk for other 
athletes. One implication of this strategy/model would be that a substance would never be considered for 
inclusion in the Prohibited List just because it is misused in sport but rather considered purely on the basis 
of available scientific evidence that it (potentially) significantly enhances performance and at the same 
time may possess a health risk for athletes.7 	
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1 The ‘trade-off between harms and benefits’ refer to the trade of harm and benefit of the present doping 
control model/anti-doping system as compared with a system in which ‘doping’ is legalised under 
medical supervision when focus is placed on athletes working conditions, occupational health, and well-
being.   
2 Elite sport can be understood as a working place, not only for professional sports but also athletes 
pursuing double careers who likewise are required full time engagement, usually involve in contractual 
agreement with federations/clubs and face performance-related expectations (Mayer & Thiel, 2016).  
3 Actors (players) in the sports figuration are, for example, elite athletes, sub-elite athletes, junior athletes, 
age-group athletes, coaches, administrators, sport physicians and other experts, family and peers, clubs, 
team owners, sports organisations, event organisers, anti-doping authorities, politicians, governmental 
institutions (e.g. responsible for the national elite support model), the legal system, healthcare, corporate 
sponsors, fans, drug supply networks, pharmaceutical companies and global media networks. 
4 These features need to be considered when assessing: i) which model for the regulation of drugs in sport 
is most suitable (or less harmful); and ii) which unique characteristics do individual harms and social 
harms have in elite sport environments.  
5 For example asthma medicines; diet medicines containing for example Pseudoephedrine or Ephedrine; 
intravenous infusions and/or injections of more than 50ml per 6 hour period. 
6 Heuberger et al., (2017) found that rHuEPO treatment enhanced performance in well-trained non-
professionals in a laboratory-based maximal exercise test leading to exhaustion, but did not improve 
submaximal exercise test or road race performance. Subsequently several researchers critically 
commented on the article or the study design (cf. Erythropoietin on cycling performance, The Lancet, 
Haematology, 4(10), Oct, 2017), for example, the study did not include a pre-test of road race 
performance, thus, differences in initial performance and in pacing and drafting strategies could not be 
controlled for (Bejder et al., 2017).  Several studies found rHuEPO to significantly enhance performance 




increase in red blood cell mass, but treatment may simultaneously increase recovery speed, have 
psychological effects on fatigue and motivation, have an effect on skeletal muscle and the immune 
system and improve lipolysis (Heuberger et al., 2017).  
7 The scientific evidence behind doping in elite competitive sport is rather scarce, partly because it is 
impossible to do intervention studies with banned substances on elite athletes who are subject to the 
WADA regulations (Heuberger et al., 2017). 	
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a The number of years at elite level was calculated from the year the athletes reported that they were 
first selected for a national team training squad or an international competition by their federation. 
b Competed once or more at a the World Championship or the Olympics as a junior and/or in the elite 
category  
c Note: these numbers are based only on the answers from the participants (71%, n=549) who 
participated in the current study and another survey assessing how athletes perceive doping and anti-
doping efforts (Overbye, 2013).The percentage illustrates the share of athletes who believe that AAS, 
GH and blood doping (respectively) have an effect (great effect, some effect or little effect) in their 
sport. The numbers in parentheses refer only to the percentage of athletes who regard the substance 







Table 1: Participants’ characteristics 
N=775 Total Sport type 






Sport type 100% 48% 23% 18% 11% 
Gender Male 60% 57% 66% 66% 57% 
Female 40% 43% 35% 34% 43% 
Mean age (SD) 21.73 (5.56) 20.94 (4.88) 22.17 (5.86) 22.22 (5.42) 23.44 (7.23) 
Years at elite 
level a 
Less than 4 
years 36% 39% 29% 35% 38% 
4-8 years 36% 36% 38% 41% 26% 
9 years or 
longer 28% 25% 33% 24% 36% 
Competed in the World 
Championships or Olympics b 
58% 39% 72% 74% 79% 
Athletes’ beliefs 
that AAS, GH or 
blood doping 
would have an 




83% (26%) 88% (28%) 91% (32%) 88% (28%) 40% (4%) 
GH 
(great effect) 84% (22%) 90% (25%) 89% (30%) 86% (19%) 44% (2%) 
Blood doping 






Figure 1: The substances/methods athletes would be interested in trying if these were legal and could be provided 
under qualified medical supervision.  
Note 1: 60% (n=55) of the 93 athletes in the current study diagnosed with asthma answered yes or most likely yes to 
the use of “Respiratory dilators (e.g. some asthma medicines)”. In contrast, only 19% of the athletes who were not 
diagnosed asthma (and who had not experienced any asthma symptoms) would most likely be interested in 
respiratory dilators if permitted in sport.  
Note 2: The respondents were not informed about the potential performance-enhancing impact (which will vary 
according to sports type). The categorisation of products was carried out by the author and relates to: i) the products’ 
classification on the prohibited list, i.e. specified vs. non-specified substances; the status of prohibition, i.e. prohibited 
at all times, only in-competition or in some sports; and ii) evidence about performance-enhancing effects regarding 
EPO, blood transfusions, AAS and GH (e.g. Lundby et al., 2008; Birzniece, 2017).  
Very performance enhancing: these are all non-specified substances/methods, prohibited at all times: AAS (S1); 
growth hormone (S2), EPO (S2) and blood transfusions (M1).  
Performance enhancing: Cortisone: prohibited when administered by oral, intravenous, intramuscular or rectal routes 
(specified: S9); stimulating substances, e.g. Ephedrine (prohibited in competition: specified S6a; non-specified: 
S6b); beta blockers: prohibited in competition and out of-competition in particular sports (specified: P2); cognitive 
enhancing means, e.g. Ritaline (specified: S6b); respiratory dilators (e.g. S1, S3; specified and non-specified, 
inhaled).  
Optimising/special needs: diuretics [specified; S5]; diet medicines, some diet medicines can contain prohibited 
substances (e.g. non-specified S6a; specified S6b thresholds); intravenous infusions and/or injections: prohibited if 
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Drop with sugar and salt as restitution between competitions  
Vitamin or mineral injections 
Diet medicine (e.g. Letigen) 
Diuretics 
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Cognitive enhancing means (e.g. Ritaline, Adderal) 
Medicine to reduce nervousness (e.g. Beta blockers) 
Stimulating substances (e.g. ephedrine/pseudoephedrine) 
Cortisone  
EPO or similar means (e.g. CERA, NESP) 
Growth Hormone  
Blood transfusions with own blood  
































































Figure 2: The probability that an athlete would be interested in trying EPO or similar 
medicines (e.g. CERA, NESP) if legal and provided under qualified medical supervision 







































Figure 3: The probability that an athlete would be interested in trying AAS if legal and 
provided under qualified medical supervision according to gender, age and type of sport. 










































Figure 4. Athletes’ considerations of side-effects if ‘doping’ was legal and provided under qualified 
medical supervision and how a fear of side-effects has an impact on athletes’ interest in drugs. No 
differences were found between athletes of different genders, age group or type of sport.   
Note: The impact of side-effects on athletes decisions can depend on the specific substances/methods. 
Therefore, athletes can answer they would refrain from one or more substances because of their fear of 
side-effects in relation to these, however, at the same time, chose not to refrain from another/other 













When you answered the 
previous question:  
Did you think about 
whether or not the 
substance/ method 
could have any side 
effects?    
8%  
Yes, but I was not afraid 
of side effects  
(n=53) 
59% 
Yes, and I was afraid of 
side effects   
 (n=383) 
77% (39% of the total) 
answered -- because of 
their fear of side effects --  
‘no’, 'most likely not’ or ‘I do 
not know’ to one or more of 
the substances 
 (n=254)   
=> 154 elaborated on which 
side effects they feared  
35% (18% of the total) 
answered -- despite their fear 
of side effects -- ‘yes’ or 
‘most likely’ to one or more of 
the substances,  
 (n=115) 
33% 
No, I did not think about 





Table A1: Contextualisation: Patterns of sport-related use of legal products, doping proximity, competition logic and the environment 
 
N=775 Total Sport type 
 
 





Patterns of sport-related use of selected legal products a      
Caffeine pills   
(prohibited in sport 
before 2004 in doses 
>12µg/ml) 
 
Systematic use  2% 0.3% 1% 10% 0% 
Non-systematic use  4% 1% 7% 10% 0% 
Previously used 3% 2% 4% 9% 2% 
Never (not yet) b 90% 97% 89% 71% 98% 
Additional selected 
vitamins and minerals, 
e.g. vitamin B12, iron, 
magnesium  
Systematic use  22% 14% 28% 40% 18% 
Non-systematic use  14% 15% 11% 16% 12% 
Previously used 13% 13% 16% 14% 2% 




Systematic use  10% 8% 17% 12% 4% 
Non-systematic use  5% 7% 5% 4% 1% 
Previously used 15% 18% 9% 17% 9% 
Never (not yet) d 70% 67% 69% 67% 86% 
Experience with ‘in sport’ use of NSAIDs e 61% 60% 63% 69% 50% 
Have never (consciously) decided to refrain from or 
minimise the use of legal products f  
39% 37% 45% 27% 51% 
How athletes say they would react if (when) some 
competitors start using a new legal performance-
enhancing drug g 
     
Use the same product and find other ways to enhance 
performance  
9% 7% 10% 13% 7% 
Use the same product 7% 4% 9% 11% 10% 
Seek to enhance performance, but not necessarily using 
the same product  
29% 28% 29% 33% 28% 
Focus on myself and do as I normally do 55% 62% 51% 43% 54% 
Influence (or not) of coach’s/sports organisation’s opinion 
regarding use of specific legal performance enhancing 
drugs  
     
The coach is against it h 78%(21%) 76%(23%) 77%(21%) 88%(12%) 71%(29%) 
Team Denmark/ the federation is against it i 78%(21%) 79%(20%) 75%(24%) 85%(16%) 73%(27%) 
Doping proximity: Knows someone who uses or has 
previously used doping j  




a  The patterns of use of legal substances/methods was explicitly linked to a sporting purpose, i.e. patterns of the use of 
drugs in relation to optimising/enhancing performance and taking care of the body by using different substances/methods 
as a supplement to normal physical training. The table displays three out of the 27 performance optimising and 
enhancing strategies measured (see Overbye, 2013: 123). 
b  The athletes who had not (yet) used caffeine pills were asked if they were interested in trying caffeine pills in the future: 
Yes = 4% / Will maybe = 13% / No = 67% / No, because I do not think it has an effect in my sport = 17%. Note: no 
gender difference were found among the 21% of endurance sports athletes who use caffeine pills, but younger 
endurance athletes (of both genders) are more likely to not (yet) use caffeine pills. Caffeine drinks were used 
systematically or non-systematically in: Team Sport = 18% /Speed and Power = 22% /Endurance = 28% / Motor Skill 
Sport = 21%.  
c  The athletes who had not (yet) used additional selected vitamins and minerals in their sport – with a sporting purpose – 
were asked if they would like to do so in the future: Yes = 21% / Will maybe = 41% / No = 30% / No, because I do not 
think it has an effect in my sport = 8%. 
d  The athletes who had not (yet) used creatine were asked if they were interested in using it in the future: Yes = 9% / Will 
maybe = 22% / No = 56% / No, because I do not think it has an effect in my sport = 13%.  
e  NSAIDs is short for Non Steroidal Anti-Inflammatory Drugs. The percentage covers the athletes who have used NSAID in 
their sport once or more.  
f  Reasons for not having (consciously) decided to refrain from using legal products (n=274) were: 27% felt it was important 
to seek to enhance performance with all available legal means; 38% did not see why one should refrain from using legal 
means; 24% reported they always followed their coaches’/experts’ recommendations and trusted that these were 
optimal; 52% had never come across a legal means that they felt the need to refrain from using or minimise the use of 
(Overbye, 2013: 138)  
g The answers to the four categories of possible reactions were formulated based on the different patterns of responses 
found in interviews with elite athletes (Overbye, 2013).  
h  The numbers not in parenthesis give the proportion of athletes who report to be less likely to want to use the drug if the 
coach is against it; the proportion of athletes who say the coach’s opinion has “no influence” is displayed in parenthesis. 
1% reported that if their coach was against the drug, it would “increase” their wish to use it.  
i The numbers not in parenthesis give the proportion of athletes who report to be less likely to want to use the drug if Team 
Denmark or their federation is against it; the proportion of athletes who say that Team Denmark and their federation 
sports opinion have “no influence” is displayed in parenthesis. 0.7% reported that if Team Denmark or their federation 
was against the drug, it would “increase” their wish to use it.  
j The percentage gives the proportion of athletes who answered that they knew someone who doped or had doped. The 
numbers in parenthesis refer to the percentage of athletes who answered “maybe, but I am not absolutely sure”. Note: 
these numbers are based purely on the answers from the participants (71%, n=549) of the current study and another 
survey assessing how athletes perceive doping and anti-doping efforts (Overbye, 2013).  
k The percentages give the proportion of athletes who answered that the statement “Corresponds completely” or “fairly well” 




In their training environment  14%(5%) 13%(5%) 20%(9%) 12%(2%) 6% (6%) 
In their sport 24%(12%) 23%(10%) 27%(15%) 29%(11%) 13%(15%) 
From other sports 23(12%) 23%(15%) 30%(11%) 16%(12%) 23%(12%) 
Friends and acquaintances outside sport 25%(8%) 23%(6%) 29%(8%) 16%(9%) 25%(13%) 
Assessment of athlete’s own training environment: 
competition logic, norms, performance and power k 
     
The athletes with the best results/best performances have 
most influence  85% 91% 82% 76% 74% 
The coach gives most attention to the athletes with the 
best results  63% 62% 69% 58% 61% 
It is important to show that one is willing to make sacrifices 
for the sport  94% 94% 89% 93% 83% 
A specific bodily appearance (e.g. trimmed, skinny, 






Theme Athletes elaboration on side-effects  
Naming the particular 




Harm/damage to body and health (29); fear of negative impact on life, e.g. physical 
and mental health after sports career has ended (17); blood clots (13); hormone 
levels (7); damage to organs, e.g. liver, kidneys, heart (7); fear of side-effects in 
general or unknown side-effects (7); fear of dependency (6); early death (6); fear of 
heart problems/heart attack (5); mental illness (5) or mental side-effects in general 
(5); high blood pressure (3); heart seizure (3); virility (4), sexual side-effects, e.g. 
impotence (3); general fear of side-effects of medicine (3); cancer (2); impact on 
physical appearance (2); acne (2); mood swings (2); mental side-effects, e.g. 
depression (2), small testes (2); aggressiveness (1); side-effects associated with 
substances that increase muscle mass (1), illness (1), side-effects of one substance 
will lead to use of other substances that can be dangerous (1); arteriosclerosis and 
other symptoms which impact lifestyle (1); stiff heart muscles (1); thick blood (1); 
reduced quality of life (1); not safe, fear of needles (1); related to gender ? (1); 
mutating cells (1); tiredness (1); dizziness (1); weakening of the bone density (1).   
Naming the specific 
substance or method they 
feared 
Fear of anabolic steroids, e.g. testosterone (22); fear of EPO (13); fear of growth 
hormone (8), blood transfusion (4), cortisone (2), diet medicine (1) 
Reservations when 
answering the question 
Need to have control of the side-effects first (2), need to be sure it is safe (1); AAS 
have side-effects, but assumption is that they will be provided under medical 
supervision (1) faith in qualified medical supervision (1); I answered, ’I do not know’ in 
the cases where I wasn’t sure if the substance would damage my health; if it does, I 
certainly won’t use it (1) 
Other explanations and 
comments 
Not natural (2), Lack of insight, knowledge and agreement between doctors, and 
therefore, I do not dare trust them (1); I want to be responsible for my own 
performance (1); Is it worth it? (1); I do not want to do this to my body (1); I said no to 
steroids and cortisone, etc. because I do not believe the effect offsets the side-effects 
(1), I am aware of side-effects regarding all the listed substances (1); I do not 
consider side-effects but want to be as good as possible with the body I have got and 
not improve performance level by ingesting the best substances (1); No matter what 
side-effects they might have, I would feel like I went from practising a healthy sport to 
destroying myself (1); I do not want to experiment with my body (1); I would NEVER 
use medicines which CAN harm the body, illegal or not (1) Others (7). 
 
Table A1: The numbers in parentheses indicate the number of athletes reporting on the particular issue. 
Answers from 154 athletes who elaborated on what side-effects they considered when answering the first 
question. 
	
	
	
